AbbVie 2026: Revenue $17.4B, Net income $4.22B, EPS $2.37— 10-Q Summary
AbbVie reported 2026 revenues of $17.4B, up 10.3% YoY, and net income of $4.22B, a 2167.7% increase. EPS rose to $2.37. Nine-month revenue grew 11% to $49.4B, driven by U.S. demand. Skyrizi and Rinvoq saw 25% and 23% growth, respectively. The company announced U.S. manufacturing investments and a $100B R&D pledge.
How this was made
The 30-second read
Why it matters
The combination of large reported EPS/revenue improvement and multiple product and regulatory milestones can shift near-term expectations for earnings quality and pipeline progress, but the summary format limits visibility into guidance and segment-level drivers.
Market read
Traders can use the reported EPS and revenue jump plus FDA approval and franchise growth to reassess near-term earnings momentum and pipeline sentiment.
What to watch
Humira biosimilar-driven decline is explicitly noted; traders may focus on whether Skyrizi and Rinvoq growth fully offsets that erosion and how quickly the oncology pipeline converts into revenue.
Background
The piece summarizes AbbVie’s SEC 10-Q (Nov. 3, 2026) with quarterly financial highlights and selected business updates, including franchise growth and an FDA approval.
Ticker impact
AbbVie reports 2026 net revenues of $17.4B, net income of $4.22B, and diluted EPS of $2.37, plus product and FDA approval updates.
Likely upward bias as the market prices in stronger earnings power and franchise momentum, tempered by ongoing Humira biosimilar decline.
The article provides concrete quarterly financials and multiple business highlights (Skyrizi, Rinvoq growth, FDA approval, and manufacturing/R&D pledge) that typically drive earnings-related repricing.
Market effects
Reinforces positive demand signals for immunology and specialty pharma franchises, potentially supporting sentiment across large-cap pharma peers.
US-focused manufacturing and R&D investment pledge may be read as supportive for domestic pharma capex and supply-chain confidence.
FDA approval and oncology submission pipeline are US regulatory signals that can influence global investor risk appetite for specialty pharma.
Counterpoint
The EPS surge is partly a comparison to a very low prior-year EPS figure, so investors may discount the magnitude until margins, cash flow, and guidance details are confirmed in the full filing.
Key entities
- companyAbbVie Inc.
US-listed pharma company reporting quarterly financials and business updates including Skyrizi, Rinvoq, and an FDA approval for Juvmo.
